DSCC1在癌症患者生存预后、免疫微环境、免疫治疗和癌症药物治疗中的作用机制

doi:10.3969/j.issn.1671-7171.2024.12.004

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (3444 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨DNA复制和姐妹染色单体内聚因子1 (DSCC1)在癌症患者生存预后、免疫微环境、免疫治疗和癌症药物治疗中的作用机制。【方法】采用癌症基因组图谱(TCGA)、基因型组织表达(GTEx)、人蛋白图谱(HPA)、肿瘤免疫评估资源2.0(TIMER2.0)、单细胞测序数据库(CancerSEA)、基因/蛋白相互作用搜索工具(STRING)、GEO免疫治疗队列和GDSC药敏数据库分析DSCC1在癌症患者生存预后、免疫微环境、免疫治疗和癌症药物治疗中的作用机制。【结果】DSCC1 mRNA在25种不同类型的癌症组织中高表达,与11种癌症患者的预后不良相关。免疫微环境结果显示:DSCC1 mRNA表达与多种免疫细胞显著相关,包括各种类型的T辅助细胞、嗜酸性粒细胞、巨噬细胞、肥大细胞等。进一步的研究表明,DSCC1 mRNA表达异常的患者有望在免疫治疗的基础上获得更好的疗效。富集分析显示:DSCC1 mRNA表达与细胞周期、p53信号通路等显著相关。【结论】DSCC1是癌症发生、发展、诊治的关键分子,其影响肺腺癌的药物治疗效果,DSCC1在多种癌症中起重要作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	龚洲平
	王宁军
	黄亮
	龙斐

关键词 ：肿瘤, 预后, DNA,肿瘤, 免疫疗法, 药物疗法

Abstract：【Objective】To investigate the role of DNA replication and sister chromatid cohesion factor 1 (DSCC1) in survival prognosis, immune microenvironment, immunotherapy and cancer drug therapy in cancer patients.【Methods】Cancer Genome Atlas (TCGA), Genotypic Tissue Expression (GTEx), Human Protein Atlas (HPA), Tumor Immune Evaluation Resource 2.0 (TIMER2.0), single cell sequencing database (CancerSEA), Interactive gene/protein Search tool (STRING), GEO immunotherapy cohort and GDSC drug sensitive database agents were used to analyze the role of DSCC1 in survival prognosis, immune microenvironment, immunotherapy and cancer drug therapy in cancer patients.【Results】DSCC1 mRNA was highly expressed in 25 different types of cancer tissues and was associated with poor prognosis in patients with 11 types of cancer. The results of immunomicroenvironment research showed that the mRNA expression of DSCC1 was significantly correlated with a variety of immune cells, including various types of T helper cells, eosinophils, macrophages, mast cells, etc. Further studies predicted that patients with abnormal DSCC1 expression were expected to achieve better outcomes of immunotherapy. Enrichment analysis showed that the mRNA expression of DSCC1 was significantly correlated with cell cycle and p53 signaling pathway.【Conclusion】DSCC1 is a key molecule in the occurrence, development, diagnosis and treatment of cancer, and it affects the therapeutic effect of lung adenocarcinoma. DSCC1 plays an important role in a variety of cancers.

Key words： Neoplasms Prognosis DNA,Neoplasm Immunotherapy Drug Therapy

收稿日期: 2024-08-29

中图分类号:

R73

基金资助:湖南省卫生健康委科研项目(编号:202103021743)

引用本文:

龚洲平, 王宁军, 黄亮, 龙斐. DSCC1在癌症患者生存预后、免疫微环境、免疫治疗和癌症药物治疗中的作用机制[J]. 医学临床研究, 2024, 41(12): 1836-1840.
GONG Zhouping, WANG Ningjun, HUANG Liang, et al. Analysis of DSCC1 in Survival Prognosis, Immune Microenvironment, Immunotherapy and Cancer Drug Therapy in Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(12): 1836-1840.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.12.004 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I12/1836

[1] SANTUCCI C, CARIOLI G, BERTUCCIO P, et al. Progress in cancer mortality, incidence, and survival: a global overview[J].Eur J Cancer Prev,2020,29(5):367-381.
[2] STENSTROM J, HEDENFALK I, HAGERLING C. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression[J].Breast Cancer Res,2021,23(1):27.
[3] XIE X W, WANG X Y, LIAO W J, et al. Effect of upregulated DNA replication and sister chromatid cohesion 1 expression on proliferation and prognosis in hepatocellular carcinoma[J].Chin Med J (Engl),2018,131(23):2827-2835.
[4] MERKLE C J, KARNITZ L M, HENRY-SANCHEZ J T, et al. Cloning and characterization of hCTF18, hCTF8, and hDCC1. Human homologs of a Saccharomyces cerevisiae complex involved in sister chromatid cohesion establishment[J].J Biol Chem,2003,278(32):30051-30056.
[5] BATRA R, HARDER N, GOGOLIN S, et al. Time-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdown[J].PLoS One,2012,7(12):e50988.
[6] YAMAGUCHI K, YAMAGUCHI R, TAKAHASHI N, et al. Overexpression of cohesion establishment factor DSCC1 through E2F in colorectal cancer[J].PLoS One,2014,9(1):e85750.
[7] JIN G C, WANG W S, CHENG P, et al. DNA replication and sister chromatid cohesion 1 promotes breast carcinoma progression by modulating the Wnt/β-catenin signaling and p53 protein[J].J Biosci,2020,45:127.
[8] WANG X, WU Y, LIU J L, et al. Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis[J].Toxicol Appl Pharmacol,2022,452:116169.
[9] KIM J T, CHO H J, PARK S Y, et al. DNA Replication and Sister Chromatid Cohesion 1 (DSCC1) of the replication factor complex CTF18-RFC is critical for colon cancer cell growth[J].J Cancer,2019,10(24):6142-6153.
[10] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J].Neoplasia,2017,19(8):649-658.
[11] SZKLARCZYK D, GABLE A L, NASTOU K C, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J].Nucleic Acids Res,2021,49(D1):D605-D612.
[12] TANG Z F, LI C W, KANG B X, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J].Nucleic Acids Res,2017,45(W1):W98-W102.
[13] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J].CA Cancer J Clin,2022,72(1):7-33.
[14] SOTAK M, SUMOVA A, PACHA J. Cross-talk between the circadian clock and the cell cycle in cancer[J].Ann Med,2014,46(4):221-232.
[15] SHAKYA R, TARULLI G A, SHENG L, et al. Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer[J].Oncogene,2017,36(31):4469-4480.
[16] HARJUNPAA H, LLORT ASENS M, GUENTHER C, et al. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment[J].Front Immunol,2019,10:1078.
[17] LIN W, ZHANG H L, NIU Z Y, et al. The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden[J].BMC Women's Health,2020,20(1):126.